The role of bispecific antibodies in the treatment landscape for R/R DLBCL

The important role of bispecific antibodies in the future treatment of R/R DLBCLПодробнее

CAR-T & bispecific antibodies in second-line DLBCLПодробнее

Bispecific antibodies for R/R aggressive B-cell lymphomasПодробнее

How Bispecific Antibodies WorkПодробнее

The role of bispecific antibodies in the treatment of R/R large B-cell lymphomaПодробнее

The future of bispecific antibodies in the treatment and management of R/R follicular lymphomaПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

Where do bispecific antibodies fit into the large cell lymphoma treatment landscape?Подробнее

The emerging potential of bispecific antibodies as monotherapy & in combination for B-cell lymphomaПодробнее

Treating Lymphoma with Bispecific Antibodies | LRF WebinarsПодробнее

Perspectives on Novel Antibody Platforms in DLBCLПодробнее

The use of ADCs & bispecific antibodies before and after CAR-T therapy in third-line DLBCLПодробнее

An insight into how bispecifics are changing the lymphoma treatment landscapeПодробнее

How Are Bispecific Antibodies Being Used in Diffuse Large B-Cell Lymphoma Treatment?Подробнее

The benefits of bispecific antibodies over CAR-T cell therapy in lymphomaПодробнее

Understanding Bispecific AntibodiesПодробнее

The evolving treatment landscape of R/R LBCLПодробнее

Weighing up the pros and cons of CAR-T therapy and bispecific antibodies in R/R DLBCLПодробнее

Current & future outlooks on CAR-T therapy & bispecific antibodies in follicular lymphomaПодробнее